• About us
• Contact

Advertisement

Organisation › Details

SpinChip Diagnostics ASA

January 13th 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”), a privately held Norwegian diagnostics company that has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted to near patient testing as it can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments. bioMérieux has held a minority stake in SpinChip since March 2024. SpinChip is initially developing lab-quality tests to address indications that are common in acute care settings, and in particular Myocardial Infarction (MI) which is a leading cause of morbidity and mortality worldwide. Current diagnostic methods based on high-sensitivity cardiac troponin assays, have significantly improved the accuracy of MI diagnosis but are still lacking fast turnaround times due to sample transportation and processing time. This often leads to prolonged Emergency Departments stays and increased health care costs due to delays in diagnosis. *

 

	Start	2012-01-01 established
	Group	Mérieux (Group)
	Industry	point-of-care diagnostic device
	Person	Jurs, Morten (SpinChip Diagnostics 202501 CEO formerly Pronova BioPharma 201109 CEO)
	Region	Oslo
	Country	Norway
	Street	21723 Hoffsveien
	City	0275 Oslo
	Tel	+47-404-99-200
		Address record changed: 2025-01-13
Basic data	Employees	n. a.
		* Document for »About Section«: bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux Strengthens Its Point of Care Presence with the Acquisition of the Immunoassay Start-up SpinChip". Marcy l’Étoile.
		Record changed: 2025-01-13

Advertisement

More documents for Mérieux (Group)

• [1] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux Strengthens Its Point of Care Presence with the Acquisition of the Immunoassay Start-up SpinChip". Marcy l’Étoile....
• [2] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux to Present at the 43rd Annual J.P. Morgan HealthCare Conference". Marcy l’Étoile....
• [3] bioMérieux S.A.. (1/13/25). "Press Release: SpinChip Diagnostics to be Acquired by bioMérieux". Oslo....
• [4] Mérieux NutriSciences Corporation. (10/7/24). "Press Release: Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing Business of Bureau Veritas". Chicago, IL....
• [5] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
• [6] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
• [7] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
• [8] Weezion SAS. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
• [9] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
• [10] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.